ACT Genomics Opens Third Laboratory in Asia at Hong Kong Science Park


ACT Genomics Holdings Co., Ltd, a leading cancer precision treatment solution provider, opened its third Next Generation Sequencing (“NGS”) laboratory in Asia at the Hong Kong Science Park, an innovation and technology centre spearheaded by the Hong Kong Science and Technology Parks Corporation. The opening ceremony was officiated by Ms Annie CHOI, Commissioner for Innovation and Technology; MrAlbert WONG, Chief Executive Officer of Hong Kong Science and Technology Parks Corporation (“HKSTP”); together with ACT Genomics management team. On top of enhancing our clinical capability, the new laboratory can serve pharmaceutical companies in such areas as biomarker and target discovery, drug development and clinical trials, allowing the Group to capture tremendous business opportunities going forward, not just in Hong Kong and Macau, but also other cities in the Greater Bay Area. Moreover,this Hong Kong laboratory will serve as the Group’s corporate financeheadquarters, helping it foster closer ties with the investment community inthe city deemed an international financial hub.

Image title